There’s more data about reinfections now, and it looks

New Post Public Reply Private Reply Replies (1) Message Board
AlwaysSum1ElsesFault JLang #60185
688
There’s more data about reinfections now, and it looks like some get it worse on reinfection. FDA, if it’s found they are intentionally delaying Leronlimab’s availability, will be faced with no choice soon, I believe.

https://www.theguardian.com/world/2020/oct/06...ts-puzzled

Quote:

Many researchers took heart from the case, but since the patient came to light a flurry of reinfections around the world have raised fresh concerns. Within days of the Hong Kong case being made public, doctors in the US reported that a 25-year-old man from Reno, Nevada, had been hospitalised with a Covid-19 reinfection after shrugging off an earlier brush with the disease. More cases soon followed. While most infections were no worse the second time around, a good number cropped up – in the US, the Netherlands, Ecuador and India – where the reinfection was more severe.

In a report on reinfected healthcare workers in India, Prof Jayanthi Shastri and her team at Kasturba hospital for infectious disease in Mumbai describe a 25-year-old nurse who suffered more with a reinfection two months after her first battle with coronavirus. “Her immunity wasn’t enough to protect her from the second, more severe infection despite the presence of neutralising antibodies,” Shastri said.
The finding, and similar cases, has refocused attention on a handful of questions that scientists are struggling to answer. What does protective immunity look like? How long does it last? Do some patients fail to mount the right response? Does the virus damage the immune system? And are reinfected people infectious to others?
Danny Altmann, professor of immunology at Imperial college in London, guesses that those who recover from Covid-19 will have perhaps 90% protection for a “fair while”. But how long is that? “I would bet my house on you being safe for possibly a year but not much longer,” he said. “The problem is that whenever an immunologist says anything about Covid immunity to a journalist, it’s right for about two weeks and then it’s completely wrong.”
Reinfections may be worse for a whole host of reasons. The person might have been exposed to more virus the second time around, or may simply have been under the weather already when the virus struck again.
Another possibility is so-called antibody-dependent enhancement – a glitch in the immune system where antibodies help an invading virus rather than hinder it. This is seen in dengue fever where second infections can be far more dangerous than the first.

Yet another possibility is that the virus harms T-cells, in some patients at least. “We need to study the T-cells,” said Swapneil Parikh, who worked with Shastri on reinfected hospital workers. “Is the virus doing something to the immune system that is setting you up for more severe infections?”
The virus can certainly disrupt the immune system. In August, Shiv Pillai, an immunologist at the Ragon Institute of Massachusetts general hospital, examined tissue taken from dead Covid-19 patients. He looked for structures called “germinal centres” in the spleen and lymph nodes. These are where B-cells go to develop antibodies before they are stored in the immune system’s memory. Pillai failed to find any, suggesting the patients were unable to generate highly effective, long-lasting antibodies that would fight the virus for years.
He believes the same problem may arise in people with milder Covid-19 too. “If we want antibodies that will persist for a few years and protect us, it’s not clear that’s going to happen,” he said. The good news is that a vaccine should not cause the same problem as the virus. “I don’t see why the vaccines won’t work. They may not be fantastic, but I believe that’s what’s going to protect us,” he said.

If the virus spreads further through the autumn and winter, Iwasaki expects to see more reinfections, with some patients infectious enough to pass the virus on.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 50

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Univers Partners to Propel Physical AI Across Industries

Updated Category News Views 145

Univers Sets Sights on Global Physical AI Expansion Now here's a tune we've been humming for a while—AI is coming to take over the mundane, and Univers seems to think it's got the right band together to make that a full-blown concert in the built environment. Announced right in the heart of Antalya, Türkiye, at the esteemed COP31, we're seeing Univers grab hands with...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 25

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
MatterSeek Platform Revolutionizing Materials R&D Worldwide

Updated Category News Views 83

Innovating the R&D Landscape with MatterSeek In the ever-changing realm of materials research and development, Yuyao Technology's latest innovation, MatterSeek, is a game changer. It's a slick launch, folks, redefining how we look at the R&D landscape through its AI-driven abilities. This ain't just another pie-in-the-sky platform; it's an actual workhorse designed to...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 155

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 10

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
AdMaven's Mave AI: Revolutionizing Campaign Management

Updated Category News Views 19

Taking the Tedious Out of Advertising You've got to love it when technology actually makes life easier, rather than more complicated. AdMaven's latest fancy toy, the AI assistant Mave, is promising just that. It's designed to take the heavy lifting off advertisers' shoulders, especially the day-to-day grind of tweaking ad settings and monitoring performance. If you've...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 101

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 104

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading

Top 5 Most Recently Viewed Articles

Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
Class Actions Alert: Understanding Investor Rights for SOC, LMT, NVO, LINE

Updated Category News Views 213

Understanding Class Action Lawsuits for Shareholders In today’s fast-paced investment world, shareholders must stay informed about class action lawsuits that may affect their investments. A recent alert highlights key class actions involving four publicly-traded companies, offering investors a glimpse into their rights and potential next steps. Sable Offshore Corp....

Continue Reading
Exploring ONCT-534: New Insights on Advanced Prostate Cancer

Updated Category News Views 202

Recent Updates on ONCT-534 for Advanced Prostate Cancer Oncternal Therapeutics, Inc. (NASDAQ: ONCT) has unveiled encouraging updates regarding its investigational therapy, ONCT-534, specifically targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). This exciting development stems from the company’s ongoing Phase 1/2 Study, known as...

Continue Reading
GDS Holdings Celebrates Successful IPO of C-REIT in Shanghai

Updated Category News Views 197

GDS Holdings Completes C-REIT IPO on Shanghai Stock Exchange Shanghai, China — GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698), a prominent developer and operator of high-performance data centers, has recently triumphantly finished its initial public offering (IPO) for the China REIT (C-REIT) on the Shanghai Stock Exchange. This achievement marks a significant milestone...

Continue Reading
Surge in Russian Stocks: MOEX Russia Index Reaches New Heights

Updated Category News Views 255

Russian Stocks Experience Notable Gains In recent trading sessions, Russian stocks showed significant upward movement, showcasing the resilience of various sectors within the economy. With the MOEX Russia Index closing higher, this is an indication of investor optimism and market recovery. Key Contributors to Market Gains Sector Performance Highlights The increase in the...

Continue Reading